Free tool
FAERS Monitor: Zaynich
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220787 or its brand name (Zaynich, Cefepime Hydrochloride, Zidebactam). Reports on generic versions are filed under their own applications.
Reports
1
Serious
1
100% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- acute kidney injury1
- encephalopathy1
- liver function test increased1
- off label use1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,158 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| liver function test increased | 1 | 979.7 | 966.7 | 244 |
| encephalopathy | 1 | 856.4 | 845.8 | 213 |
| acute kidney injury | 1 | 137.4 | 136.8 | 34 |
| off label use | 1 | 24.0 | 24.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.